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Atherosclerosis is a systemic pathological process
associated with important clinical acute complications
(acute coronary syndrome, fatal and nonfatal ST-elevation
myocardial infarction, sudden death) that are not strictly
related to its extent and severity. The first clinical
manifestation of ischemic heart disease is variable and
characterized by acute events in about 50% of cases.1
Approximately half of all acute coronary events occur in
patients without prior cardiac symptoms or diagnosis.2
The early identification of individuals at risk is desirable
to activate a more effective preventive strategy. Currently,
the risk of future clinical events of ischemic heart disease is
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prediction models (ie, Framingham Risk Score, PROCAM,
SCORE, Pooled Cohort Equations), integrating nonmodifi-
able risk factors (RFs) such as age, gender, and a family
history of early ischemic heart disease, along with
modifiable conventional RFs such as arterial hypertension,
hypercholesterolemia, smoking, and diabetes mellitus.3–5
Although risk assessment by current recommended
scores based on traditional RFs is useful to assess the
mean cardiovascular risk in a given population, it has
limitations concerning individual variability.6,7 Indeed,
many individuals who develop acute coronary events
would be classified at low or intermediate risk by the
traditional RF-based approaches.8–13 Conversely, many
individuals with an adverse RF profile remain asymp-
tomatic for years, thus suggesting the presence of
protective mechanisms.14
A meta-analysis including 122,458 patients who expe-
rienced acute coronary events confirmed that the risk
proportionally increased with RF number, but approxi-
mately 15% men and 20% women did not have any of 4
conventional RFs.13 Similarly, the analysis of the CHA,
MRFIT, and FHS trials revealed that patients exposed to at
least 2 RFs had a higher risk of cardiac death; however,
70% of subjects with the same risk profile died of other
nonischemic causes.14 Therefore, the exposure to several
RFs is not enough to account for clinical events in all
subjects, and still unknown environmental and genetic
factors may play a role in the pathophysiology of
coronary artery disease (CAD).
These findings, despite the significant population
attributable risk of conventional RFs,15 support the
need to search novel RFs reflecting different atherogenic
aspects to improve cardiovascular event prediction16
and identify new and accurate biomarkers17 for subjects
at higher risk, who are potential targets for personalized
prevention programs. In addition, the identification of
yet unknown protective factors may suggest specific
therapeutic strategies.
The complex relationship among traditional RFs, CAD
and clinical manifestation of ischemic heart disease is
the object of the CAPIRE study. This study sought to
analyzed the outlier populations at the opposite ex-
tremes for the presenceof coronary computed tomography
angiography (CCTA)–documented CAD and traditional
cardiovascular RFs.
Through this novel approach, the study is aimed (1) to
detect new protective and susceptibility factors of CAD
and ischemic events, thus enabling the definition of
specific descriptors (clinical, imaging, and circulating
biomarkers) for the still unrecognized individuals at the
highest risk; (2) to identify new pathophysiological keys
of interpretation of the complex relationship among
clinical (including lifestyle habits), anatomical variables of
CAD, and circulating biomarkers (cross-sectional phase);
(3) to follow up all subjects for a period of 5 years(longitudinal phase) to investigate whether coronary
events are more closely correlated with RFs than with
coronary atherosclerosis; and (4) to collect and store in a
dedicated biological bank blood samples from each
selected subject.
Methods
CAPIRE study
The CAPIRE study (ClinicalTrials.gov Identifier:
NCT02157662) is part of the GISSI Outlier Project jointly
promoted by the Heart Care Foundation Onlus, Italian
Association of Hospital Cardiologists (ANMCO) and Mario
Negri Institute of Pharmacological Research, Milan. The
research strategy of the project is focused on individuals,
defined as “outliers,” who diverge from the average
prevalent behavior predicted by current models.
The CAPIRE study was designed as a prospective,
observational, and international multicenter study involv-
ing (1) a cross-sectional comparison of clinical, imaging,
and biomolecular variables between extreme selected
populations and (2) a longitudinal phase in which
subjects will be initially followed up for a 5-year period.
Study population
The study population was selected among both male
and female subjects aged 45 to 75 years, without any
previous clinical manifestations of ischemic heart disease,
who underwent 64-slice (or superior) CCTA in the
outpatient clinics of the 11 centers involved in the
study, because of suspected CAD.
Themain indications for CCTAwere (1) uninterpretable,
equivocal, or contraindicated functional stress test in 44.3%
of patients and (2) new-onset chest pain syndrome at
low-intermediate pretest likelihood of CAD in 24.7% and
other indication (including preoperative evaluation before
valve or noncardiac surgery, elevated risk profile, arrhyth-
mias, or atypical symptoms) in 31.0%.
Risk factors and CAD definition. The conventional
cardiovascular RFs based on Adult Treatment Panel III3
and 2013 American College of Cardiology/American
Heart Association (AHA) guidelines for cardiovascular
prevention18 were considered for the selection process
of the study population.
Risk factors were defined as follows: family history of
ischemic heart disease (history of early manifestations of
ischemic heart disease in first-degree relatives, with onset
b55 years old formen andb65years old forwomen), arterial
hypertension (history of arterial hypertension, ongoing
antihypertensive treatment, or recent observation of blood
pressure values N140/90 mm Hg), hypercholesterolemia
(total cholesterol values N200 mg/dL or b200 mg/dL with
ongoing lipid-lowering medications), diabetes mellitus
(fasting plasma blood glucose levels N126 mg/dL or 2-hour
values in the oral glucose tolerance test of ≥200 mg/dL or
isolated elevation of glycated hemoglobin≥6.5% or current
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smoking (current cigarette smoking habit or recent
abstention (b1 year).
The source of data for defining cardiovascular RFs was
physical examination, anamnestic records, and laboratory
tests reported by the subject or documented before CCTA.
After the enrollment, a centrally performed biomarker
profile including lipid profile and metabolic markers
allowed to refine the assessment of RFs such as diabetes
and hypercholesterolemia.
Within enrollment criteria, the choice of risk cutoffs for
the different populations based on the number of RFs
aims at providing simple enrollment criteria. According
to data reported in the literature,3 most patients without
any RFs or one single RF belong to risk group b10% of
events at 10 years according to Framingham Study and
patients with 3 or more RFs belong to risk group N20% of
events at 10 years. Subsequently, for the whole enrolled
population, the risk assessment according to different
scores (Framingham Risk Score, SCORE, Pooled Cohort
Equations) will be carried out.
Diabetes as single RF has been excluded because of
evidence of its own higher cardiovascular risk3 as well as
for the development of CAD and being independently
associated with the atherosclerotic burden.19
Coronary atherosclerotic plaque was defined as any
clearly discernible structure that could be assigned to the
coronary artery wall and that could be discriminated from
surrounding pericardial tissue and epicardial fat. Normal
coronary arteries were defined if no atherosclerotic
plaque (including focal and eccentric calcified plaques)
could be detected in any segment within the coronary
artery wall or lumen.
The choice of CCTA as a selection method for
dichotomic outlier populations is based on the comple-
mentarity of relevant specific diagnostic performance
and selection criteria for the study population.20
Coronary computed tomography angiography allows
for noninvasive assessment of coronary anatomy, pro-
viding evidence of the presence, extent, and severity of
CAD, vascular wall, remodeling process, and plaque
characteristics. The high negative predictive value of
CCTA enables to identify subjects with normal coronary
arteries in a direct and more accurate manner than other
noninvasive methods. On the other hand, regardless of
stenosis quantification, CCTA can better detect segments
with subclinical disease, thus accurately defining the
overall atherosclerotic process.21
A 5-coronary-segment involvement cutoff was set to
define a diffuse CAD. This choice was based on
previously demonstrated prognostic value22,23 and on
the results of CONFIRM registry that showed a strong
role of CCTA in the prediction of all-cause mortality at
2-year follow-up, when individuals were partitioned
into groups with a segment involvement score (SIS) of
≤5 vs N5.24This population represents the platform to work for
further innovative investigations carried out in homoge-
neous outlier groups selected by the integration of
clinical, imaging, and first-line biomarker profiles.
Therefore, basedonCCTA result andRFburden (Figure 1),
2 outlier groups have been identified:
- No-CAD/High-RF: subjects with no CAD and 3 or
more RFs
- CAD/Low-RF: subjects with diffuse CAD extended to
more than 5 of the 16 segments according to the AHA
classification25 and 0-1 RFwith the exclusion of patients
with type 1 or type 2 diabetes mellitus as single RF
Thus, using the same criteria, 2 control groups have
been selected, consisting of the following:
- No-CAD/Low-RF: subjects with no CAD and 0-1 RF
with the exclusion of patients with type 1 or type 2
diabetes mellitus as single RF
- CAD/High-RF: subjects with diffuse CAD extended
to more than 5 of the 16 segments according to the
AHA classification25 and 3 or more RFs
Exclusion criteria were as follows: CCTA did notmeet the
quality control criteria, previous cardiovascular events
(acute myocardial infarction, unstable angina, chronic
stable angina, previous percutaneous or surgical coronary
revascularization, heart failure), both clinically evident and
confirmed by conventional diagnostics; previous heart
disorders documented or identified at CCTA, such as dilated
cardiomyopathy regardless of etiology, obstructive hyper-
trophic cardiomyopathy, atrial fibrillation, myocarditis, and
inflammatory vascular disease; previous documented acute
or chronic peripheral vascular disease (stroke, transient
ischemic attack, previous percutaneous, or surgical vascular
revascularization; claudication at rest/low-grade effort); and
active inflammatory or neoplastic disease.
Baseline examination
Patients satisfying the inclusion criteria had a structured
interview concerning conventional RFs, medical history,
previous cardiovascular examinations, and ongoing
therapies. During the enrollment examination, anthropo-
metric data and blood pressure were also recorded as
well as a rest 12-lead electrocardiogram, questionnaires
on psychosocial factors (Hospital Anxiety and Depression
Scale-Anxiety, Hospital Anxiety and Depression Scale-De-
pression, and Type D Scale-14), and dietary habits.
The whole study population had a peripheral venous
blood sample taken at baseline and after 2 years of follow-up.
The samples were treated to obtain 0.5 mL whole blood,
plasma, and serum aliquots and stored in a freezer at −70°C.
Samples of each subject enrolled in the studywere collected
in a single dedicated biological bank (SATURNE-1; Mario
Negri Institute of Pharmacological Research, Milan, Italy).
Figure 1
Graphical representation of the selection criteria of the study population and flow diagram of selection process after CCTA core laboratory
evaluation and central biochemical assay. CCTA core laboratory evaluation excluded overall 16 patients because of the low image quality or 1 ≤
SIS b 5. Central biochemical assay refined the assessment of RFs such as diabetes and hypercholesterolemia, and 47 patients scheduled in the low-
RF groups were reclassified and excluded because of their higher RF profile.
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All circulating biomarkers were measured in a central
laboratory, in a single batch, by personnel unaware of
patients' characteristics. Serum creatinine, glycated hemo-
globin, and lipidsweremeasuredwith standard, automated
laboratory methods. Plasma levels of pentraxin-3 (PTX3)
were measured by in-house sandwich enzyme-linked
immunosorbent assay as previously described.26 Detection
limit was 0.1 ng/mL. High-sensitivity C-reactive proteinwas
measuredwith an automatic immunoturbidimetricmethod
(Beckman-Coulter, Galway, Ireland).
Statistical analysis
Given the pure exploratory strategy and hypothesis-gener-
ating purposes using a novel approach focusing on still
uninvestigated outlier populations, the definition of popula-
tion size was difficult to assess using traditional hypothesis--
driven statistical methodology.
A preliminary retrospective observational, multicentric
analysis has been performed by examining the existing
databases of 3 participating centers to collect data about the
proportion of patientswhomet the inclusion criteria during a
median timeof 1.5 years. This analysiswas aimed to assess the
prospective study feasibility according to inclusion criteria.
The retrospective study indicated that, among 619 subjectswith absence of CAD at CCTA, 79 (12.8%) had ≥3 RFs
(no-CAD/high-RF group), whereas among 157 patients with
diffuse CAD, 56 (35.7%) had 0-1 RFs (CAD/low-RF group).
Continuous variables were presented as mean with SD
or as median with interquartile range (25°-75°) if more
appropriate (nonnormal distribution). Continuous vari-
ables normally distributed were compared using the
Student t test for independent samples. When the variable
distribution was not normal, Mann-Whitney U tests for
independent samples were used. The proportion of the
categorical variables was compared using a χ2 analysis or
Fisher exact test, as appropriate. A P value b.05 was
considered statistically significant. Estimated odds ratios
and accompanying 95% CIs are presented for each class
of the variables that became significant at the univariate
analysis. Statistical analysis and graphics were produced
with SAS (version 11; SAS Institute Inc, Cary, NC).
Funding
The study is promoted by GISSI Group (ANMCO, Mario
Negri Institute and Heart Care Foundation Onlus). The
sponsor of the study is the Heart Care Foundation Onlus,
a nonprofit independent institution. The study is partially
supported by an unrestricted grant by Ferrero Spa and
from the contributions collected by the Heart Care
Table. Baseline characteristics of the outlier groups
No CAD P CAD P P between outlier
groups CAD/LR vs
no CAD/HRLow-RF High-RF Low-RF High-RF
n (%) 201 (41.8) 120 (24.9) 65 (13.5) 95 (19.8)
Demographic
Age (y), mean (SD) 58.2 ± 8.6 58.7 ± 8.0 .60 64.2 ± 7.5 63.2 ± 6.9 .37 b.0001
Sex, M/F (%) 49.8:50.2 42.5:57.5 .21 93.8:6.2 71.6:28.4 .0005 b.0001
RFs
Family history of IHD (%) 7.0 65.0 b.0001 7.7 60.0 b.0001 b.0001
Arterial hypertension (%) 21.4 85.8 b.0001 30.8 91.6 b.0001 b.0001
Dyslipidemia (%) 47.8 96.7 b.0001 43.1 94.7 b.0001 b.0001
Current smoking (%) 4.5 46.7 b.0001 6.2 57.9 b.0001 b.0001
Diabetes (%) 0 24.2 b.0001 0 37.9 b.0001 b.0001
BMI (kg/m2), mean (SD) 25.1 ± 3.7 27.4 ± 3.9 b.0001 26.8 ± 4.1 28.1 ± 4.6 .051 .34
Systolic BP (mm Hg), mean (SD) 125.1 ± 13.5 129.1 ± 14.6 .017 128.4 ± 13.3 135.2 ± 16.1 .0037 .75
Laboratory data
Total cholesterol (mg/dL), mean (SD) 195.2 ± 39.3 205.4 ± 46.5 .046 188.0 ± 31.8 181.7 ± 45.0 .30 .003
LDL cholesterol (mg/dL), mean (SD) 119.3 ± 32.5 125.0 ± 35.9 .15 120.0 ± 28.9 111.5 ± 36.9 .106 .3
HDL-C (mg/dL), mean (SD) 55.2 ± 16.0 51.7 ± 14.7 .043 45.0 ± 9.7 45.6 ± 12.5 .744 .0003
Triglycerides (mg/dL), median (IQR) 73 (54-105) 111 (78-184) b.0001 104 (72-142) 113 (84-168) .146 .22
Glycated Hb (%), median (IQR) 3.4 (3.2-3.8) 3.6 (3.2-3.9) .0154 3.4 (3.2-3.9) 4.0 (3.4-4.6) b.0001 .07
C-reactive protein (mg/L), median (IQR) 1.2 (0.5-2.7) 1.7 (0.9-4.5) .002 1.5 (0.5-4.6) 2.4 (0.8-5.9) .26 .5
PTX3 (ng/mL), median (IQR) 3.2 (2.1-4.8) 2.6 (1.8-4.7) .18 3.4 (2.5-5.7) 3.0 (2.0-4.9) .085 .06
Serum creatinine (mg/dL), mean (SD) 0.80 ± 0.16 0.80 ± 0.19 .97 0.91 ± 0.2 0.85 ± 0.18 .07 .0008
Values are expressed as mean ± SD, median (IQR, 25°-75° percentile) or no. (%).
LR, low-risk; HR, high-risk; M/F, male-to-female ratio; IHD, ischemic heart disease; BMI, body mass index; BP, blood pressure; LDL, low-density lipoprotein; IQR, interquartile range;
Hb, hemoglobin.
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March 2016Foundation Onlus, in the years 2009 and 2010, from the
fundraising campaigns “Accendi il tuo cuore.”Results
Based on the results from a preliminary retrospective
analysis, a total of 544 consecutive patients were recruited
in the study from January 2011 to June 2013. The on-site
preliminary selection, based on CCTA angiograms and on
the presence of RF, allowed to select a whole study
population with a mean age of 60.2 ± 8.4 years and a
predominance of men (58.5%).
Two “outlier” groupswere identified: 120 (22.1%) patients
with absence of CAD despite 3 or more RFs (no-CAD/
high-RF group) and93 (17.1%) patientswith diffuseCADand
0-1 RF excluding diabetes as single RF (CAD/low-RF group).
The control groups included 229 (42.1%) patients with no
CAD and 0-1 RF excluding diabetes as single RF (no-CAD/
low-RF group) and 102 (18.7%) patients with diffuse CAD
and 3 or more RFs (CAD/high-RF group).
In order to verify the extreme and phenotypically
homogeneous features of the outlier populations, each
CCTA was analyzed by the core laboratory. Glycemic and
lipid profiles were also assessed by central analysis to reduce
the biased exclusion of RFs only by the anamnestic report.
As shown in Figure 1 after the CCTA core laboratory
evaluation, 1 patient of no-CAD/high-RF and 15 patients of
CAD/low-RF were excluded. Moreover, central biochem-
ical assay allowed to refine the assessment of RFs such asdiabetes and hypercholesterolemia, and 20 patients
scheduled in the CAD/low-RF group, in addiction to 27
patients preliminary selected in the no-CAD/low-RF group,
were reclassified and excluded because of their higher
RF profile. Therefore, the final outlier population consisted
of 185 patients: 120 patients in the no-CAD/high-RF group
and 65 patients in the CAD/low-RF group. Baseline
characteristics of 2 outlier groups are reported in Table.
In the CAD/low-RF group, SIS and segment stenosis score
were 7.6 ± 2.1 and 11.3 ± 5.0, respectively. Furthermore,
CCTA documented obstructive coronary disease with
stenosis N50% in 49 (75.4%) patients, of whom 29
(44.6%) had stenosis N70%. The composition of the plaque
wasmainly calcified plaques (70.5%),whereas noncalcified
plaque was only 8.7%.
The CAD/low-RF group was significantly older than the
no-CAD/high-RF group (64.2 ± 7.5 vs 58.7 ± 8.0 years,
respectively; P b .0001), with prevalence of men (93.8% vs
42.5%, respectively; P b .0001).
The RF distribution exhibited opposite and extreme
features; most of the CAD/low-RF group patients had 1 RF
(87.7%) with the exclusion of diabetes as a single RF. In
the no-CAD/high-RF group, 3 RFs were reported in 82.5%
patients, 4 RFs were reported in 16.7%, and only 0.8% of
patients had all the RFs.
As shown in Figure 2, also the RF presence significantly
diverged among groups. Patients in the CAD/low-RF
group showed hypercholesterolemia (43.1%) and arterial
hypertension (30.8%), whereas family history of ischemic
Figure 2
Number of RFs and RF distribution within the 2 outlier groups, CAD/low-RF and no-CAD/high-RF.
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smoking in 6.2%.
In the no-CAD/high-RF group, hypercholesterolemia
(96.7%), arterial hypertension (85.8%), and family history
of ischemic heart disease (65.0%) largely occurred; 46.7%
was active smokers; and 24.2% had diabetes.
Regarding anthropometric variables, body mass index
mean values were not different between the 2 outlier
groups. The mean total cholesterol value was significantly
higher in patients in the no-CAD/high-RF group, but mean
serum low-density lipoprotein cholesterol and median
triglycerides values did not differ between groups. Note-
worthy, the treatment with statins was significantly higher
in the no-CAD/high-RF group than in the CAD/low-RF group
(56.7% vs 12.3%; P b .0001).
The mean high-density lipoprotein cholesterol (HDL-C)
was significantly higher in the no-CAD/high-RF group
(51.7 ± 14.7 mg/dL) than in the CAD/low-RF group
(45.0 ± 9.7 mg/dL; P = .0003). Furthermore, the outlier
populations showed different serum creatinine mean levels
even within the reference range (0.91 ± 0.2 [CAD/low-RF
group] vs 0.8 ± 0.19 [no-CAD/high-RF group], P = .0008).
Regarding inflammatory markers, there were no difference
between the 2 groups for median levels of C-reactive
protein and PTX3.Discussion
We presented here the study design and rationale of the
CAPIRE study developed with the aim to investigate, withan innovative approach focused on the outliers individuals,
new protective and RFs regarding the development of
diffuse coronary atherosclerosis and the onset of different
clinical manifestation of ischemic heart disease.
First, our preliminary results demonstrate that 2 outlier
populations can be detected in the clinical field of
patients who undergo CCTA for routine clinical reasons.
Among individuals without previous cardiovascular
history investigated for suspected CAD, CCTA allows to
identify 2 relevant outlier populations: (1) subjects with
no CAD and multiple RFs, and 2) at the opposite extreme,
subjects with diffuse CAD (SIS N5), with higher expected
risk of events, despite a low RF burden.
The central analysis of CCTA and biomarkers guaran-
teed a rigorous control of both imaging and RF inclusion
criteria and allowed to allocate outlier populations at the
extreme and opposite RF distribution, thus preventing
selection bias that characterizes a retrospective analysis.
The baseline clinical characteristic of the study population
highlighted the opposite RF burden between the 2 outlier
groups. Furthermore, the preliminary univariate and unad-
justed analyses allow to identify age, gender, HDL-C, and
serumcreatinine as distinctive variables among the 2 groups.
During the study, we collected biological samples from
outlier population in a Bio-Bank. These samples will be used
to identify and characterize novel environmental and
genetic RFs through the assessment of known and emerging
markers of lipid, metabolic, thrombotic, inflammatory,
immunologic, and genetic profile. Advanced “-omic”
(genomic, proteomic, and transcriptomic) investigations
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selected by the integration of clinical, imaging, and first-line
biomarker profiles.
Our preliminary data combined to previous studies and
our retrospective preliminary analysis confirmed the
existence of outlier subjects, thus supporting that the
presence of RFs was neither a necessary nor a sufficient
condition for atherosclerosis development, but unknown,
genetic, environmental, and individual factors may play a
critical role in disease development. These preliminary
findings challenge the generalization of the widely
accepted simplistic paradigm of a straightforward relation-
ship between RF and CAD, and thus, they could stimulate
new avenues for research.
Several bodies of evidence have suggested that the
relationship between RFs and coronary events appears to
be valid only to a first approximation in population
analyses and in specific subgroups. Autoptic27 and
angiographic28 studies and analyses with intracoronary
ultrasound19 or coronary artery calcium (CAC) indicated
that the relationship among RFs and the extent of
coronary atherosclerosis was weak and variable.29,30
The individual variability of the relationship between
CAD and RFs was also reported using CCTA. Indeed,
Faletra et al31 demonstrated that after CCTA in subjects
without previous clinical manifestations of ischemic
heart disease, about 18% of patients with CAD did not
show any conventional RFs, whereas 12% of subjects
with no CAD had at least 3 RFs. Consistently, Johnson
et al32 demonstrated that the individual amount of
CAD burden detected at CCTA was not closely related
to the National Cholesterol Education Program score
risk categories.
Recently, Silverman et al30 in theMESA cohort confirmed
the evidence of CAC heterogeneity in individuals at the
extremes of traditional risk classification. Indeed, among
the population with CAC 0 the absolute risk of coronary
heart disease event remained low for a mean of 7.1 years of
follow-up, although RFs were associated with higher
relative risk. These findings emphasize the challenging
issue concerning which protective factors patients with
CAC 0 and exposed to multiple RFs have.
In our prospective study, we sought to detect,
characterize, and collect either clinical and imaging data
or biological samples of these outlier populations in order
to investigate still unknown risk or protective factors for
coronary atherosclerosis and ischemic events.
Among individuals investigated for suspected CAD, our
results demonstrated the ability of CCTA for the
identification of 2 relevant populations of outliers:
patients who have no CAD despite multiple RFs and
those who have extensive CAD with ≤1 RF.
In our study, the outlier groups were characterized by
different distributions of age and gender, which became
the greatest determinants of both risk and protection for
atherosclerotic process, regardless of the modifiable RFs.In all major cohorts, age became the single strongest RF
related to future cardiovascular events and the female
gender was a strong protective factor (for the age range
considered in the study). Indeed, a minority of women
were found in the CAD/low-RF group.
However, the impact of aging and gender in coronary
risk prediction models might inadvertently deemphasize
new risk or protective factors that can be modifiable early
in life and that can greatly affect long-term outcomes. Any
future investigation will take into account this issue, and
the analysis should be adjusted, in particular for age and
gender, in order to detect the added value of new
predictive variables.
A first-line biomarker profile including lipid profile,
inflammatory, and metabolic markers such as hemoglo-
bin A1c and serum creatinine was assessed to charac-
terize the outlier population with a wide broad of
circulating markers as well as to further select biological
homogenous subgroups.
The outlier population showed significantly different
mean HDL and serum creatinine values, consistently with
the well-established association between both HDL and
renal function and CAD in large populations. The
detection of these significant difference also in a small
but homogenous oppositely extreme population further
supports the potential value of a study of outlier
population as an innovative strategy to investigate
multifactorial diseases (eg, ischemic heart disease),
particularly for hypothesis-generating purposes.
Indeed, the bias of large and nonhomogeneous
populations and the confounding effect of different
pathogenetic variables are reduced, whereas the detec-
tion of significant individual protective or risk biomo-
lecular markers can be enhanced also in a relatively
small-sized population. This approach has recently been
proposed for genome-wide association studies to
increase study efficiency of complex phenotypes.33Limitations
The principal limitation of the CAPIRE study is its
pure exploratory strategy and hypothesis-generating
purposes using a novel approach focusing on poorly
studied outlier populations. Thus, the definition of
the population size is difficult to assess using
traditional hypothesis-driven statistical methodology.
Indeed, the sample size could be an important
limitation of the study. However, as expected, the
outlier patients are rare and we reported a feasible
approach to study them.
However, the opposite and extreme features of
inclusion criteria of the CAPIRE study based on opposite
RF burdens and CCTA anatomical disease categories
(normal coronary arteries vs SIS N5) with divergent
prognostic value can further improve the detection of
potential differences among small-sized population.
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risk profile based only on the presence of the traditional
RFs. Anyway, according to Adult Treatment Panel III,
most patients with 0-1 RF belong to the risk group b10%
of events at 10 years according to Framingham Study and
patients with 3 or more RFs belong to risk group N20% of
events at 10 years.3
Conclusion
Analyzing the clinical, imaging, and biomolecular variables
of apparently healthy individuals at the extremes for the
relationship between traditional RF profile and the presence
of CAD documented by CCTA, the CAPIRE study would
allow for the investigation of novel protective and suscep-
tibility factors for CAD and ischemic events, distinguishing
the causal role of coronary atherosclerosis from that of RFs,
independently from age and sex.
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